UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049446
Receipt number R000056303
Scientific Title Survey about impact of COVID-19 symptoms on daily life and labor productivity
Date of disclosure of the study information 2022/11/08
Last modified on 2023/09/25 18:27:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Survey about impact of COVID-19 symptoms on daily life and labor productivity

Acronym

Survey about impact of COVID-19 symptoms on daily life and labor productivity

Scientific Title

Survey about impact of COVID-19 symptoms on daily life and labor productivity

Scientific Title:Acronym

Survey about impact of COVID-19 symptoms on daily life and labor productivity

Region

Japan


Condition

Condition

COVID-19

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To characterize COVID-19 patients who require an antiviral treatment at home or accommodation by surveying the clinical feature, clinical course, and impact on daily and social life of COVID-19 symptoms.

Basic objectives2

Others

Basic objectives -Others

Aggregate and analyze the results of COVID-19 web survey.
COVID-19 survey items
1)Symptoms, severity of symptoms, duration of symptoms
2)Impact on social and daily life by symptoms
3)Time until work/study/housework can be done
4)Importance of early COVID-19 symptoms disappearance
5)Importance of prevention of the transmission of SARS-CoV-2 to contacts
6)Importance of earlier test negative for SARS-CoV-2
7)Anxiety/fear with risk of household transmission, death, sequelae
8)Satisfaction with the treatment

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Outcomes for COVID-19 survey items
1)Symptoms, severity of symptoms, duration of symptoms
2)Impact on social and daily life by symptoms
3)Time until work/study/housework resuming
4)Importance of early COVID-19 symptoms disappearance
5)Importance of prevention of the transmission of SARS-CoV-2 to contacts
6)Importance of earlier test negative for SARS-CoV-2
7)Anxiety/fear with risk of household transmission, death, sequelae
8)Satisfaction with the treatment

Key secondary outcomes

Outcomes for post-acute COVID-19 syndrome survey items
1)Symptoms, severity of symptoms, duration of symptoms
2)Impact on social and daily life by symptoms
3)Time until work/study/housework can be done
4)Impact on work/school/housework productivity
5)Changes in the work environment (changes in work content, leave of absence, retirement, job change)
6)Anxiety/fear with post-acute COVID-19 syndrome


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Those who were diagnosed with COVID-19 during April to August 2022 and had symptoms
2)Those who were treated at home or accommodation

Key exclusion criteria

Those who do not consent to this survey

Target sample size

2000


Research contact person

Name of lead principal investigator

1st name Masaya
Middle name
Last name Yamato

Organization

Rinku General Medical Center

Division name

Division of General Internal Medicine and Infectious Diseases Center for Infectious Diseases

Zip code

598-8577

Address

2-23 Rinku Ourai-Kita, Izumisano, Osaka 598-8577, Japan

TEL

072-469-3111

Email

m-yamato@rgmc.izumisano.osaka.jp


Public contact

Name of contact person

1st name Shintaro
Middle name
Last name Tanaka

Organization

Shionogi & Co., Ltd.

Division name

Medical Affairs Department

Zip code

100-0005

Address

1-8-2, Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan

TEL

080-2409-3174

Homepage URL


Email

shintarou.tanaka@shionogi.co.jp


Sponsor or person

Institute

Shionogi & Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Shionogi & Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Non-Profit Organization MINS Research Ethics Committee

Address

5-20-9-401, Mita, Minato-ku, Tokyo, Japan

Tel

03-6416-1868

Email

npo-mins@j-irb.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 11 Month 08 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

2000

Results

The patient-reported symptoms and those impact on daily lives in acute and post-quarantine period were similar regardless of presence/absence of risk factors for severe disease. This may suggest an appropriate treatment is needed not only patients with risk factors but also patient without risk factors.

Results date posted

2023 Year 09 Month 25 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 10 Month 27 Day

Date of IRB

2022 Year 11 Month 02 Day

Anticipated trial start date

2022 Year 11 Month 09 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2022 Year 11 Month 07 Day

Last modified on

2023 Year 09 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056303


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name